Cystic Fibrosis in Focus
Cystic fibrosis (CF) is one of the most prevalent global congenital disorders, affecting some 70,000 individuals worldwide and 30,000 children and adults in the United States. While clinical efforts are expanding worldwide to improve diagnostic testing and treatment approaches for this progressive lung disease, targeted therapies for CF against any specific mutation remain elusive.
The Cystic Fibrosis in Focus series gathers the latest information from leading medical experts devoted to advancing knowledge in pursuit of treating patients with CF. With education spanning topics such as pinpointing CF's underlying genetic basis, identifying specific mutations, improving clinical detection methods, and providing more targeted therapies, The Cystic Fibrosis in Focus series delivers the critical tools needed to improve care for CF patients.
In Partnership with
Episodes 1-4 of 4
An In-Depth Look at the Evolution of Cystic Fibrosis Treatments
Clinician's RoundtableAn In-Depth Look at the Evolution of Cystic Fibrosis Treatments
Journal of Cystic Fibrosis: Efficacy and Safety of Levofloxacin Inhalation Solution (APT-1026) in Stable Cystic Fibrosis Patients
AudioAbstractsJournal of Cystic Fibrosis: Efficacy and Safety of Levofloxacin Inhalation Solution (APT-1026) in Stable Cystic Fibrosis Patients
Journal of Cystic Fibrosis: Microbial Colonization and Lung Function in Adolescents With Cystic Fibrosis
AudioAbstractsJournal of Cystic Fibrosis: Microbial Colonization and Lung Function in Adolescents With Cystic Fibrosis
Cell Death and Differentiation: A Novel Treatment of Cystic Fibrosis Acting On-Target
AudioAbstractsCell Death and Differentiation: A Novel Treatment of Cystic Fibrosis Acting On-Target